Cristal Therapeutics develops a proprietary polymeric platform, registered as CriPec, that allows for the transiently stable entrapment of active compounds in nanoparticles. Numerous in vivo validation studies confirm that CriPec nanoparticles significantly improve the efficacy and safety of various entrapped compounds when compared to conventional drugs used in several therapeutic areas. The clinical development of CriPec docetaxel is part of company’s strategy to leverage CriPec into a portfolio of bestin-class products using small molecules, peptides, and actively targeted nanoparticles.

Cristal Therapeutics was founded in April 2011, as a spin-off of the Department of Pharmaceutics of Utrecht University by Cristianne Rijcken, PharmD PhD, and Joost Holthuis, PhD.